Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer

GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in relapsed/refractory multiple myeloma as compared with daratumumab (Darzalex) plus bortezomib and dexamethasone, coming full circle in a bid to return to the U.S. market after withdrawal in 2022.

China-based BeiGene announced a rebranding as BeOne Medicines. (EndPoint News)

MRI guidance for stereotactic body radiation to treat prostate cancer led to a significant reduction in toxicity and improvement in patients’ quality of life. (UCLA Health, European Urology)

In a small preliminary clinical study, an investigational cancer vaccine induced immune responses in hard-to-treat triple-negative breast cancer. (WashU Medicine, Genome Medicine)

Patients with prostate specific membrane antigen-positive metastatic castration-resistant prostate cancer lived significantly longer without disease progression when treated with the radioligand ¹⁷⁷Lu-PSMA-I&T versus hormonal therapy, Curium Pharmaceuticals announced.

Royal Philips announced FDA clearance of its detector-based spectral CT radiotherapy solution designed to deliver more personalized treatment for cancer.

A clinical trial of the targeted drug revumenib in relapsed/refractory NMP1-mutant acute myelogenous leukemia met the primary endpoint of complete remission plus complete remission with partial hematological recovery, Syndax announced.

A virology scientist recounts the experience of treating her own breast cancer with viruses she grew in a laboratory. (Inside Hook)

Biomarker-guided therapy informed by ctDNA analysis led to significantly better overall survival in metastatic gastrointestinal cancers. (ESMO, Nature Medicine)

A 10-second, artificial intelligence-driven analysis during surgery for brain cancer showed whether any cancer cells remained. (Michigan Medicine, Nature)

New insights into how a mushroom supplement might help slow the progression of prostate cancer. (City of Hope)

Preliminary evidence of activity in advanced gynecologic cancers emerged from an early-stage clinical trial of pembrolizumab (Keytruda) plus denileukin diftitox (Lymphir), Citius Pharma announced.

The gut microbiome could yield clues to the origin of bladder cancer. (Fox Chase Cancer Center)

“Full House” actor Dave Coulier revealed on his podcast that he has stage III non-Hodgkin lymphoma. (USA Today)

Remote skin analysis by telemedicine proved accurate for diagnosing melanoma. (NYU Langone Health, Journal of the American Academy of Dermatology)

Please enable JavaScript to view the comments powered by Disqus.